PTUPB is a novel dual acting COX-2/sEH inhibitor with IC50 of 1.26 uM/0.9 nM, also is a potent AKR1C3 inhibitor with IC50 of 65 nM.
PTUPBdoes not inhibits COX-1 (IC50>100 uM).
PTUPB reduces kidney injury parameters, decreases inflammatory and oxidative stress markers in ZDF rats.
PTUPB exhibits more effective than the same dose of either COX-2 inhibitor (celecoxib) or sEH inhibitor (t-AUCB) alone, shows in vivo antiallodynic activity in vivo.
PTUPB also suppresses glioblastoma growth by targeting EGFR and hyaluronan mediated motility receptor, potentiates the antitumor efficacy of cisplatin.
PTUPB inhibits CRPC proliferation by suppressing the AKR1C3/AR/AR-V7 axis and is more effective and superior to indomethacin.
PTUPB shows much better efficacy than indomethacin in castration-relapsed VCaP xenograft, patient-derived xenograft (PDX) organoid, and cell models generated from advanced prostate cancer patients.
